Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats

Mutsumi Kunita-Takanezawa, Kohtaro Abe, Yoshitaka Hirooka, Yukimitsu Kuwabara, Katsuya Hirano, Masahiko Oka, Kenji Sunagawa

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


The efficacy of endothelin (ET) receptor antagonist bosentan in patients with severe pulmonary arterial hypertension (PAH) remains limited, partly because its higher doses for potential blockade of ET receptors have never been tested due to liver dysfunction. We hypothesized that rigorous blockade of ET receptors using the novel dual ET receptor antagonist macitentan would be effective in treating severe PAH without major side effects in a preclinical model appropriately representing the human disorder. In normal rats, 30 mg·kg21·d21 of macitentan completely abolished big ET-1-induced increases in right ventricle (RV) systolic pressure. Adult male rats were injected with SU5416, a vascular endothelial growth factor blocker, and exposed to hypoxia for 3 weeks and then to normoxia for an additional 5 weeks (total 8 weeks). In intrapulmonary arterial rings isolated from rats with severe PAH, macitentan concentration dependently inhibited ET-1-induced contraction. Long-term treatment with macitentan (30 mg·kg21·d-1, from week 3 to 8) reversed the high RV systolic pressure with preserved cardiac output. Development of RV hypertrophy, luminal occlusive lesions and medial wall thickening were also significantly improved without increasing serum levels of liver enzymes by macitentan. In conclusion, efficacious blockade of ET receptors with macitentan would reverse severe PAH without major adverse effects.

Original languageEnglish
Pages (from-to)473-480
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Issue number5
Publication statusPublished - Nov 1 2014

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats'. Together they form a unique fingerprint.

Cite this